* Abivax SA ABVX.OQ ABVX.O is expected to report
resultson
September 9 for the period ending March 31 2024
* The Paris Ile-de-france-based company is expected to
report
revenue of €1.123 million, according to the estimate from one
analyst, based on LSEG data.
* LSEG's mean analyst estimate for Abivax SA is for a loss
of 74
cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abivax SA
is
42.00, above its last closing price of $12.28.
This summary was machine generated September 6 at 16:02 GMT.
All figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)